

# [www.fiercepharma.com/special-reports/top-10-drug-patent-losses-2014](http://www.fiercepharma.com/special-reports/top-10-drug-patent-losses-2014)

its ability to take on these investments is supported by its healthy and stable operational cash flows and a solid liquidity profile.

[www.fiercepharma.com/](http://www.fiercepharma.com/)

[www.fiercepharma.com/special-reports/top-10-drug-patent-losses-2014](http://www.fiercepharma.com/special-reports/top-10-drug-patent-losses-2014)